A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
← catalyst calendarNCT07585097 · readout in 1,868 d
Sponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
30estimated
Sites
14
Countries
France, Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-10 | actual | When the study began enrolling |
| Primary completion | 2031-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alagille Syndrome
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants experiencing adverse events (AEs)
measured From first ICF signature and up to end of data collection (approximately 5 years of data collection)
Percentage of participants experiencing serious adverse events (SAEs)
measured From first ICF signature and up to end of data collection (approximately 5 years of data collection)
Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed